<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01297803</url>
  </required_header>
  <id_info>
    <org_study_id>8772</org_study_id>
    <nct_id>NCT01297803</nct_id>
  </id_info>
  <brief_title>Comparison of Two Method Antimetabolites Application on Corneal Function in Trabeculectomy Surgery</brief_title>
  <official_title>Corneal Endothelial Cell Loss Following Trabeculectomy With mitomycin_c Application Before Versus After Sclera Flap Dissection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Application of antimetabolite agents such as mitomycin_c has improved trabeculectomy results
      and better control of intraocular pressure complications such as corneal endothelial cell
      loss. However, Mitomycin_c can be applied remain a concern before or after sclera flap
      dissection. Mitomycin_c application after sclera flap dissection probably increases corneal
      endothelial cell loss. This study compares Mitomycin_c application two methods: before and
      after sclera flap dissection with regard to success rate and complication. patients on base
      of Mitomycin_c application time (1-2-3) minutes will be match randomise in to two groups(
      before and after sclera flap dissection) corneal. Endothelial cell density, polymorphism,
      polymegathism and intraocular pressure before and one month, three months, six months after
      surgery will measured.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>corneal endothelial cell density</measure>
    <time_frame>six month</time_frame>
    <description>specular microscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>corneal endothelial cell polymorphism</measure>
    <time_frame>6 months</time_frame>
    <description>specular microscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>corneal endothelial cell polymegathism</measure>
    <time_frame>6 months</time_frame>
    <description>specular microscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IOP (intra ocular pressure)</measure>
    <time_frame>six months</time_frame>
    <description>applanation tonometry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Glaucoma Patients Scheduled for Trabeculectomy</condition>
  <arm_group>
    <arm_group_label>Mitomycin_c application before sclera flap dissection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mitomycin_c application after sclera flapdissection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin_c</intervention_name>
    <description>0.02%.1,2,3,minutes match randomized in to two groups(before &amp;after scleral flap dissection</description>
    <arm_group_label>Mitomycin_c application before sclera flap dissection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin_c</intervention_name>
    <description>0.02%.1,2,3,minutes match randomized in to two groups(before &amp;after scleral flap dissection</description>
    <arm_group_label>Mitomycin_c application after sclera flapdissection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age Range between 18 to 80 years old

          -  Trabeculectomy to JOAC, POAG, CACG, PXF, pigment dispersion syndrome.

        Exclusion Criteria:

          -  Secondary glaucoma (active uveitis, NVG, specific syndromes such as axenfeld rieger,
             Iridocorneal Endothelial syndrome, aniridia, peters, etc).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Labbafinejad medical center</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>shahin Yazdani</last_name>
      <phone>00982122585952</phone>
      <email>labbafi@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>shahin yazdani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2011</study_first_submitted>
  <study_first_submitted_qc>February 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2011</study_first_posted>
  <last_update_submitted>February 16, 2011</last_update_submitted>
  <last_update_submitted_qc>February 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Shahin Yazdani</name_title>
    <organization>Ophthalmic Research center</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Corneal Endothelial Cell Loss</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

